Status:
COMPLETED
Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.
Lead Sponsor:
GlaxoSmithKline
Conditions:
Schizophrenia
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
A PET study using \[11c\]GSK931145 to characterise the exposure-occupancy relationship over time for GSK1018921.
Detailed Description
This is an open-label, adaptive-design, single-dose, non randomized PET occupancy study.The primary aim of this study is to describe the relationship between plasma concentrations and brain occupancy ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy male subjects
- Age: 18-55 years
- No history of physical, neurological or mental illness
- Exclusion criteria
- History of claustrophobia or inability to lie still in the PET camera for at least 2 hours
- Cardiac pacemakers or metal implants in the body that contraindicate MRI scan.
- History of regular alcohol consumption (weekly intake \>21 units) within the previous six months.
Exclusion
Key Trial Info
Start Date :
May 19 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2008
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00945503
Start Date
May 19 2008
End Date
December 22 2008
Last Update
July 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Barcelona, Spain